<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study describes the pharmacokinetics of <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF) in 15 pediatric patients with <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> involving the kidney </plain></SENT>
<SENT sid="1" pm="."><plain>Patients included 10 with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 1 with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome, 2 with Wegener <z:hpo ids='HP_0002955'>granulomatosis</z:hpo>, and 1 each with <z:e sem="disease" ids="C0018085" disease_type="Disease or Syndrome" abbrv="">Goodpasture syndrome</z:e>, Henoch-Sch√∂nlein-associated <z:hpo ids='HP_0000123'>nephritis</z:hpo>, and 1 with severe <z:hpo ids='HP_0001970'>tubulointerstitial nephritis</z:hpo> and <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were treated with steroids and additional therapy prior to treatment with MMF, which was administered for a median of 491 days </plain></SENT>
<SENT sid="3" pm="."><plain>Mean starting dose of MMF was 974+/-282 mg/m(2 )in two divided doses </plain></SENT>
<SENT sid="4" pm="."><plain>Pharmacokinetic monitoring of the active compound of MMF, <z:chebi fb="0" ids="168396">mycophenolic acid</z:chebi> (MPA), was performed using an EMIT assay </plain></SENT>
<SENT sid="5" pm="."><plain>The mean MPA AUC after a median of 39 days was 61.8+/-31.0 micro gxh/ml, median time to maximum concentration was 60 min, and mean maximum concentration was 18.5+/-8.4 micro g/ml </plain></SENT>
<SENT sid="6" pm="."><plain>At last follow-up, mean MMF dose was 900+/-341 mg/m(2) per day, and mean trough MPA concentration was 3.1+/-1.1 (range 0.6-4.6) micro g/ml </plain></SENT>
<SENT sid="7" pm="."><plain>Therapy was effective in inducing remission in 4 of 9 patients with active disease </plain></SENT>
<SENT sid="8" pm="."><plain>Only 1 of the 5 other patients relapsed </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 6 patients with controlled disease maintained remission </plain></SENT>
<SENT sid="10" pm="."><plain>There were few side effects: one episode each of <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and <z:mp ids='MP_0000221'>leukocytopenia</z:mp> and two <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that MMF at 900 mg/m(2) per day appears to be effective in these patients </plain></SENT>
</text></document>